Development of a quantitative method for sunitinib N-oxide

Yuya Ishikawa, Takuya Araki, Miki Takenaka Sato, Hideaki Yashima, Daisuke Nagano, Koujirou Yamamoto

Abstract

We developed a simple method for quantifying sunitinib N-oxide (SNO) in human serum using a supported liquid extraction (SLE) method and liquid chromatography/tandem mass spectrometry (LC-MS/MS) to assess the impact of SNO on adverse drug reactions (ADRs) caused by sunitinib. SNO was extracted using an SLE method and analyzed using an Xevo-TQ (Waters) LC-MS/MS system. SNO and voriconazole (internal standard; ISTD) were detected in ESI positive mode, with transitions at 415.4/326.3 for SNO and 350.1/281.1 for voriconazole. The retention times of SNO and voriconazole were 2.25 and 2.67 min, respectively, and good calibration curve was obtained from 0.1–5.0 ng/mL for SNO. The regression equation (weight = 1/x2) describing the calibration curve in human serum was y = 2.81 × 10-9 x2 + 0.000253 x – 0.00202 (R2 = 0.990), where y is the peak area ratio of SNO against the ISTD and x is the nominal concentration of SNO. The intra- and inter-assay accuracy varied between -2.4 and 15.6% and all data except the limit of quantification (LOQ) were within ±10%. The precision varied between 6.7–15.4% and all data except LOQ were under 15%. The mean recovery ratio of SNO was 90.3 ± 4.9%, and the mean matrix factor was 0.96 ± 0.031. This is the first report of a method to quantify SNO in blood. This method will help in elucidating the effects of SNO in humans, contribute to the elucidation of the ADRs expression factors associated with sunitinib, and aid in optimizing treatment with sunitinib.

Full Text:

PDF HTML

References

James L, Abby P, Grace F, Stephen M, Connie C. First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis. Expert Opin Pharmacother. 2015;16(13):1915-27.

Olivia LS, Gilles F, Sylvie N. First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review. Clin Drug Investig. 2016;36(5):389-99.

Cancel M, Fromont G, Blonz C, Chevreau C, Rioux-Leclercq N, Laguerre B, et al. A retrospective study of the GETUG group (Groupe d’Etude des Tumeurs Uro-Génitales). Eur. J. Cancer. 2021;158(4):1–11.

Hao Z, Sadek I. Sunitinib: The antiangiogenic effects and beyond. Onco. Targets. Ther. 2016;9(8):5495–505.

Lim S, Hwang I, Ji J, Oh S, Yi J, Lim D, et al. Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. Asia. Pac. J. Clin. Oncol. 2017;13(1):61–67.

Gore M, Szczylik C, Porta C, Bracarda S, Bjarnason G, Oudard S, et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer. 2015;113(1):12–9.

Takasaki S, Kawasaki Y, Kikuchi M, Tanaka M, Suzuka M, Noda A, et al. Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma. Int. J. Clin. Oncol.2018;23(5):936–43.

Westerdijk K, Krens S, Graaf W, Mulder S, Herpen C, Smilde T, et al. The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour. Br. J. Clin. Pharmacol. 2021;87(2): 326–35.

Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K, et al. Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients with Renal Cell Carcinoma. Clin. Genitourin. Cancer. 2015;13(4):350–8.

Adams V, Leggas M. Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors. Clin. Ther. 2007;29(7):1338-53.

Werbrouck E, Bastin J, Lambrechts D, Verbiest A, Thomas Van Brussel, Lerut E, et al. ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib. Acta Clin. Belg. 2019;74(3):180-8.

Mizuno T, Fukudo M, Terada T, Kamba T, Nakamura E, Ogawa O, et al. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. Drug Metab. Pharmacokinet. 2012;27(6):631-9.

Laura W, Stephanie T, Lufang Y, Dustin L. Real-World Use of Azathioprine Metabolites Changes Clinical Management of Inflammatory Bowel Disease. J Can Assoc Gastroenterol. 2020;4(3):101–9.

Georgios S, Benedikt S, Christoph H, Gerhard G, Koen RS, Sebastian W, et al. Pharmacokinetic patterns of risperidone-associated adverse drug reactions. Eur J Clin Pharmacol. 2016;72(9):1091-8.

Takahiro Y, Yasuaki M, Tatsuya Y, Takafumi N, Junichi K. Saturated Metabolism of Voriconazole N-Oxidation Resulting in Nonlinearity of Pharmacokinetics of Voriconazole at Clinical Doses. Biol Pharm Bull. 2015;38(10):1496-503.

Shimada M, Okawa H, Kondo Y, Maejima T, Kataoka Y, Hisamichi K, et al. Monitoring serum levels of sorafenib and its N-oxide is essential for long-term sorafenib treatment of patients with hepatocellular carcinoma. Tohoku J. Exp. Med. 2015;237(3):173-82.

Takenaka M, Takahashi Y, Yashima H, Araki T, Yamamoto K. The Impact of Sunitinib N-oxide as a Photodegradation Product of Sunitinib. Indones. J. Pharm. 2019;1(1):19-25.

Amemiya T, Honma M, Kariya Y, Ghosh S, Hiroaki Kitano H, Kurachi Y., Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology. NPJ Syst Biol Appl. 2015;1(28):1-10.

Grimaldi M, Renée N, Izzedine H, Milano G. A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2009;877(29):3757-61.

Erp N, Wit D, Guchelaar H, Gelderblom H, Hessing T, Hartigh J. A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2013;937(15):33-43.

Takasaki S, Tanaka M, Kikuchi M, Maekawa M, Kawasaki Y, Ito A. Simultaneous analysis of oral anticancer drugs for renal cell carcinoma in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. Biomed. Chromatogr. 2018;32(6):1–8.

Bill S, Hai-Zhi B, William P, Geoffrey P, Ellen W, Shem P, et al. Carlo B, Ping K. Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. Drug Metab Dispos. 2012;40(3):539-55.

Matsunaga N, Kitahara T, Yamada M, Sato K, Kodama Y, Sasaki H. The influence of light sources on sunitinib measurements with photoisomerization. Biomed. Chromatogr. 2019;33(2):e4407.

Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal M, et al. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. Journal of Chromatography B. 2009;877(22):1982-96.

Posocco B, Buzzo M, Giodini L, Crotti S, D'Aronco S, Trald P. Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine. J. Pharm. Biomed. Anal.2018;160(25):360-7.

Marangon E, Buzzo M, Posocco B, Gagno S, Zanchetta M, Iacuzzi V, et al. A new high-performance liquid chromatography–tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine. J. Pharm. Biomed. Anal.2020;179(5):112949.

DOI: https://doi.org/10.24198/idjp.v3i2.37368

Refbacks

  • There are currently no refbacks.